22. Relapsed childhood lymphoblastic leukemia

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ananth Shankar

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch22

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Shankar, A. (2013) Relapsed childhood lymphoblastic leukemia, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch22

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. University College London Hospitals NHS Foundation Trust, London, UK

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • children;
  • mitoxantrone;
  • polyethylene glycol (PEG);
  • relapsed acute lymphoblastic leukaemia (ALL R3)

Summary

This chapter talks about four case studies of relapsed childhood lymphoblastic leukemia. The first case study discusses the effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3). The second case study is about comparison of high-dose with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. The third one deal with the post-relapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity. The last one is about comparison of native Escherichia coli and polyethylene glycol (PEG) asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukaemia. The chapter presents objectives, study design, statistics, and results of each cash studies.